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Abstract: 
Background: The International Prognostic Index (IPI) is used to determine 
prognosis in diffuse large B-cell lymphoma (DLBCL). One of the determinants 
of IPI is the stage of disease with bone marrow involvement being classified 
as stage IV. For the IPI, involvement on bone marrow is traditionally defined 
on the basis of histology with ancillary investigations used only in difficult 
cases to aid histological diagnosis. This study aimed to determine the effect of 
the routine use of flow cytometry, immunohistochemistry and molecular 
studies in bone marrow staging upon the IPI.  
Results: Bone marrow trephines of 156 histologically proven DLBCL cases at 
initial diagnosis were assessed on routine histology, and 
immunohistochemistry using two T-cell markers (CD45RO and CD3), two B-
cell markers (CD20 and CD79a) and kappa and lambda light chains. Raw flow 
cytometry data on all samples were reanalysed and reinterpreted blindly. DNA 
extracted from archived paraffin-embedded trephine biopsy samples was 
used for immunoglobulin heavy chain and light chain gene rearrangement 
analysis. Using immunophenotyping (flow cytometry and 
immunohistochemistry), 30 (19.2%) cases were upstaged to stage IV. A 
further 8 (5.1%) cases were upstaged using molecular studies. A change in 
IPI was noted in 18 cases (11.5%) on immunophenotyping alone, and 22 
(14.1%) cases on immunophenotyping and molecular testing. Comparison of 
two revised IPI models, 1) using immunophenotyping alone, and 2) using 
immunophenotyping with molecular studies, was performed with baseline IPI 
using a Cox regression model. It showed that the revised IPI model using 
 3
immunophenotyping provides the best differentiation between the IPI 
categories. 
Conclusions: Improved bone marrow staging using flow cytometry and 
immunohistochemistry improves the predictive value of the IPI in patients with 
DLBCL and should be performed routinely in all cases.  
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Background:  
Diffuse large B-cell lymphoma (DLBCL) is defined by the World Health 
Organization (WHO) as a heterogeneous entity, encompassing morphologic 
and genetic variants, and variable clinical presentations and outcomes (1). It 
accounts for 80% of all aggressive lymphomas (1). The median long-term 
overall survival in DLBCL is only ~40-50% (2) with variable outcomes 
depending on pre-treatment clinical and laboratory characteristics (3).   
 
The International Prognostic Index (IPI) is a standard clinical tool that is widely 
used to predict outcome for patients with aggressive Non-Hodgkin lymphoma 
(NHL), including DLBCL. It uses a number of clinical and laboratory markers 
present at the time of diagnosis to predict survival. Age > 60 years, stage III/IV 
disease defined by results of radiological investigations and bone marrow 
(BM) biopsy, elevated lactate dehydrogenase (LDH) level, Eastern 
Cooperative Oncology Group (ECOG) performance status ≥ 2 and more than 
one extra nodal site of disease, are scored 1 each, and depending on the final 
score ranging from 0-5, 4 prognostic categories are created. These are: low 
risk correlating with IPI of 0-1, low-intermediate risk with IPI of 2, high-
intermediate risk with IPI of 3, and high risk with IPI of 4-5. Five year overall 
survivals range from 73% to 26% (3). However, limitations of the IPI are well 
recognised owing to the heterogeneity in clinical outcomes within IPI groups. 
Although gene expression profiling has been used to determine subtypes of 
DLBCL based on stages of B-cell differentiation (4), such studies are largely 
limited to the research setting. Efforts to improve clinical outcomes in DLBCL 
using reliable prognostic markers are ongoing (5, 6). In this study, we 
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assessed the impact of improved staging investigations using easily available 
ancillary investigations on the IPI.  
 
BM involvement was defined using histology alone in the large multicentre 
study from which the IPI was developed (3). Ancillary tests such as flow 
cytometry, immunohistochemistry and molecular studies were not considered 
as part of staging towards the IPI. As these investigations have become more 
routinely available in laboratories around the world and their usage has 
increased, attempts have been made to define their clinical role.  Currently the 
practice of performing ancillary tests is variable, and although several centres 
may perform at least some of these tests in routine practice, their usage is not 
appropriately validated and the impact of the routine use of these tests on the 
IPI has not been formally studied. When patients with histologically inapparent 
bone marrow involvement have positive results on ancillary tests, there is 
likely to be change in the IPI.  
 
This study demonstrates that a significant change in the predictive value of 
the IPI can be brought about by incorporating ancillary investigations over and 
above routine histological diagnosis in staging bone marrows. 
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Methods:  
Patients:  
One hundred and fifty six retrospective cases diagnosed with histologically 
proven DLBCL at the Canberra Hospital from 1986-2005, on whom staging 
BM biopsies had been performed, were identified for the purpose of the study. 
After approval was obtained from the Australian Capital Territory (ACT) 
Human Research Ethics Committee, clinical information on patients was 
collected from the medical records department at The Canberra Hospital.  
 
The average age of the patient cohort was 61 years (range 20-87 years), and 
the male to female ratio was 1.5:1. Baseline staging data using routine 
staging procedures [computed tomography (CT) scan, gallium/ positron 
emission tomography (PET) scan and histological examination of BM] was 
available in 150 patients. Thirty nine (26%), 35 (23%), 45 (30%), and 31 
(21%) were found to have stage I, stage II, stage III and stage IV disease 
respectively. Baseline assessment of IPI was possible in 148 patients. Thirty 
seven (25%) had an IPI of ≤1 of which 14 (9.5%) had an IPI of 0, and 23 
(15.5%) an IPI of 1. IPIs of 2 and 3 were noted in 36 (24.3%) and 46 (31.1%) 
cases respectively. Twenty nine (19.6%) cases had an IPI of ≥ 4 of which 22 
(14.9%) and 7 (4.7%) and an IPI of 4 and 5 respectively. The mean baseline 
IPI of the patient cohort was 2.41 with a standard deviation of 1.3. 
 
Treatment data showed that of 152 patients on whom data was available, 
most were treated with anthracycline based regimens. One hundred and 
twenty nine patients (82.7%) were treated with Cyclophosphamide, 
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Doxorubicin, Vincristine and Prednisolone (CHOP) (7) or variations of CHOP 
chemotherapy protocols (8, 9). Two patients were treated with Ifosphamide, 
Carboplatin and Etoposide (ICE) (10), 5 patients with Prednisolone, Etoposide 
and Novantrone (PEN) (11), 1 with Etoposide, Vincristine, Doxorubicin, 
Cyclophosphamide and Prednisolone (EPOCH) (12), 2 with Hyper-CVAD (13) 
comprising of hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin 
and Prednisolone courses alternating with courses of Methotrexate and 
Cytarabine, 3 with Trans-Tasman Radiation Oncology group (TROG) protocol 
(14) and 1 with Methotrexate, Doxorubicin, Cyclophosphamide, Vincristine, 
Prednisolone and Bleomycin (MACOP-B) (15). Nine patients were treated 
with palliative intent with steroids alone or in combination with non-
anthracycline based drugs. Treatment details were not available in 2 patients 
and 2 were lost to follow-up. Thirty six patients (22.2%) received Rituximab. 
The median overall survival of the entire patient group was 6 years (95% 
confidence interval [CI]: 3.8, 8.4 years).  
 
BM histology: 
BM biopsies are performed as a routine assessment for all cases with DLBCL 
at first diagnosis in our institution. All trephines are fixed in buffered formalin 
and acetic acid for 24 hours and then decalcified using 5% nitric acid. 
Samples are then embedded in paraffin and sections stained with 
Haematoxylin and Eosin (H&E), giemsa stain and silver impregnation for 
reticulin. Archived H&E, giemsa and reticulin preparations on the trephine 
biopsy were retrieved for review. The mean trephine length for the patient 
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cohort was similar to our previous reports, 17.6 mm with a range of 8-36 mm 
and the mean number of levels on H&E sections were 3.7 (range 1-8). 
 
Two haematologists reviewed all slides blindly, and discrepant cases (n=20) 
were resolved by consensus. Standardised criteria were used to classify 
trephine biopsy samples as positive, negative or indeterminate (16).  
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Flow cytometry: 
Raw immunophenotypic data on all bone marrow biopsies was retrieved from 
laboratory records and re-analysed.  
 
Multiparametric flow cytometric analysis is performed in our laboratory, with 
marrow cells immunophenotypically labelled by direct four-colour 
immunofluorescence using a panel of antibodies (CD45, CD19, CD20, CD22, 
CD10, HLA-DR, Kappa, Lambda, CD2, CD3, CD5, CD7; Becton-Dickinson).   
Red cells are lysed by incubation with ammonium chloride, and cells washed 
in phosphate buffered saline after centrifugation. A cell-suspension of 1 X106 
cells per tube is incubated with the monoclonal antibody at room temperature, 
then washed and resuspended in a solution of phosphate buffered saline and 
foetal calf serum. Isotypic controls used are IgG1 and IgG2.  
 
Data acquisition is on a Becton-Dickinson flow cytometer with a minimum of 
2000 lymphocytes counted in each sample. Bright CD45 fluorescent staining 
and intermediate side scatter are employed as the primary gating strategies to 
identify the lymphocyte population, and further gating is performed as required 
based on cell size or using back gating on CD19 positive events.  
 
Previously archived raw data were reanalysed, including blinded re-
determination of the population of lymphocytes to be gated. Positive results 
on flow cytometry were defined as light chain clonal restriction with a kappa: 
lambda ratio of >3:1 or <0.3:1(17). Predominance of B-cells in the gated 
 10
population alone without light chain restriction was not considered as a 
positive result.   
 
Immunohistochemistry:  
Immunohistochemical analysis was performed on a Ventana Benchmark 
NexES machine. Sections from archived formalin-fixed decalcified paraffin-
embedded (FFDPE) trephine biopsies were immunostained using the 
streptovidin-biotin method. The following monoclonal antibodies were used: 
CD3 [Dako clone CD3, 1:200 dilution], CD45RO [Novacastra clone UCLH-1, 
1:1000 dilution], CD20 [Zymed clone L26, 1:50 dilution], CD79a [Dako clone 
JCB117, 1:500 dilution], Kappa [Novacastra clone kp-53, 1:750 dilution], and 
Lambda [Novacastra clone Hp-6054, 1:750 dilution]. All antibodies are 
validated and routinely used in our laboratory. CD20 and CD3 are reported to 
be sensitive at assigning lineage in diffuse aggressive NHL (18) and CD79a 
and CD45RO were selected over others owing to familiarity and to maintain 
consistency. These are the antibodies used for diagnostic tissue sections in 
our laboratory. Heat retrieval was used for all antibodies and tonsillar tissue 
was used as a positive control. A standardised system of reporting was 
adopted and was followed for all stains by two pathologists blinded to 
previous assessment on histology. 
 
Features used to define involvement on immunohistochemistry reflected 
standardised histology criteria. The presence of B-cell aggregates was 
classified as abnormal or malignant when there were large numbers of 
aggregates, the aggregates were large-sized, or contained disproportionate 
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numbers of larger cells. Controls (six morphologically normal marrows) were 
used to create a visual impression of normal amounts of background T and B-
cells. Scattered small or large B-cells were classified positive only when the 
numbers were substantially increased as compared to controls. A 
conservative approach was adopted to avoid false positives. Discrepancies 
between the two pathologists were resolved consensually.  
 
Molecular studies; 
Samples for molecular studies were obtained from formalin-fixed decalcified 
paraffin-embedded (FFDPE) trephine sections. DNA extraction was 
performed manually using the Roche High Pure PCR Template Preparation 
Kit from two 10-micron FFDPE trephine sections according to the 
manufacturer’s instructions. To verify the integrity of the DNA extracted from 
the paraffin sections, and to validate results, all samples were amplified with 
the control master mix provided in the Immunoglobulin heavy chain (IgH) 
gene clonality kit from Invivo Scribe Technologies based on the BIOMED2 
protocols (IgH Gene Clonality Assay – Gel Detection; InVivo Scribe 
Teachnologies, USA). This is a multiplex PCR that targets multiple genes and 
generates a series of amplicons 100, 200, 300, 400 and 600 base pairs (bp) 
in length.  
 
IgH gene rearrangement analysis was performed on all cases, targeting the 
conserved framework regions (FR) FR1 [IGHA: VHFR1-JH] and FR3 [IGHC: 
VHFR3-JH] using the Invivo scribe kit based on the BIOMED2 protocols (19).  
Only FR1 and FR3 were analysed owing to limited amounts of DNA and 
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based on reports from other groups (20). This was combined with light chain 
gene rearrangement analysis and included two reactions targeting Ig Kappa 
(IgK) variable and joining regions [IGHKA: Vk-Jk;] and IgK variable and 
intragenic regions [IGKB: Vk-Kde]. The PCR reactions consisted of 45µL of the 
FR1, FR3 or IGK master mix solution, 2.5 units of Amplitaq Gold (Applied 
Biosystems, USA) and 5µl of template DNA (with an average template DNA 
concentration of 300-400 ng/µl). Thermo cycling was performed according to 
the kit protocol with no modifications on a Perkin Elmer 9600 thermocycler. 
Controls consisted of a positive DNA control, negative extraction control and 
negative PCR control. Water was used as a negative control in both cases.  
 
Non-denaturing polyacrylamide gel electrophoresis was used to resolve the 
FR1 and FR3 PCR products. 25uL of PCR product was loaded onto a 6% 
polyacrylamide gel and 250V applied for 1.25 hours for FR1 and 1.5 hours for 
FR3 reactions.  After electrophoresis, the gels were stained with ethidium 
bromide and visualised under UV light. 
 
For the IGK reactions, PCR products were denatured at 94oC for five minutes 
and subsequently cooled at 40C for 60 minutes to induce duplex formation. 
Non-denaturing polyacrylamide gel electrophoresis was used to resolve the 
PCR products. 25uL of PCR product was loaded onto a 6% polyacrylamide 
gel and 250V applied for 1.5 hours each for both reactions.  
 
FR1, FR3 and IgK gene rearrangements were reported as clonal, polyclonal 
or not detected. The expected sizes of the PCR products were 310-360 bp for 
 13
FR1 and 100-170 bp for FR3 which together are estimated to account for 
approximately 70% of all rearrangements.(20) IGK PCR products were 
expected to be in the following ranges: 120-160 bp, 190-210 bp, 260-300 bp 
for IgKA and 210-250, 270-300, 350-390 bp for IgKB.  
 
Statistical analysis:  
Survival data were recorded for each patient. Besides descriptive analysis, 
Kaplan Meier curves were created with cumulative survival as the outcome. 
Forward stepwise multivariate Cox regression analysis using the likelihood 
ratio method was used to establish a comparison between baseline IPI and 
two revised IPI models. The first model (rIPI1) was based on routine use of 
immunophenotyping alone (flow cytometry and immunohistochemistry) and 
the second (rIPI2) was based on routine use of immunophenotyping and 
molecular results. A probability of 0.05 was used as the entry criterion and 0.1 
was considered for removal. Patients treated with palliative intent were 
excluded from all survival analyses. All analyses were performed using the 
software programme Statistical Package for Social Sciences (SPSS) version 
14.0. 
 
 14
Results: 
Histology:  
Of the 156 cases on which bone marrow histology slides were available, 24 
were positive on routine histology. Six cases were reported as indeterminate 
using Cheson criteria, and agreed upon as being positive for involvement after 
consensual review. H&E stains showed no evidence of involvement in 126 
cases.  
 
Immunophenotyping:   
Flow cytometry data was evaluable in 152 cases, of which 27 (17.3%) cases 
were noted to be positive for involvement using standardised light chain 
ratios. Ten of these 27 cases were also positive on routine histology.  
Immunohistochemistry using T and B-cell markers showed involvement in 43 
cases of 154 available cases of which involvement on routine histology was 
noted in 25/ 42 cases. One case was not comparable due to loss of H&E 
slides. Flow cytometry and immunohistochemistry each detected histologically 
inapparent involvement in 17 cases (11%).   
 
Molecular studies: 
Amplification was obtained in 133/155 cases (84.7%) with amplification at 96 
base pairs (BP), 200 bp, 300 bp, 400 bp and 600 bp noted in 125 (79.6%), 74 
(47.1%), 32 (20.4%), 25 (15.9%) and 18 (11.5%) cases respectively. Forty 
one cases of 155 evaluable ones were positive on immunoglobulin heavy and 
light chain gene analysis. Three showed no amplification on amplification 
controls. Thirty four cases were positive on light chain analysis with all 
showing a clonal band with kappa A; three cases also showed clonal 
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reactions with kappa B. Overall, 19 cases were positive on heavy chain 
analysis (FR3: 18 cases, and FR1: 4 cases) Of these, three cases were 
positive on both reactions. Overlap with light chain analysis is shown in table 
1. Overall, 12/ 41 cases were positive and 29 negative on routine histology.  
 
To establish tumour origin, DNA was extracted from 17 available primary 
FFDPE tissue blocks and gene rearrangement analysis performed. 
Comparable clonal bands could be identified in only 10 cases. Of these, 2 
were positive on routine histology.  
 
Thus, using stringent criteria to account for false positivity, routine molecular 
staging on FFDPE trephine biopsy tissue yielded positive results in eight 
(5.1%) histologically negative cases.   
   
Effect on stage and IPI:  
Thirty cases were upstaged using immunophenotyping alone with 6 cases 
upstaged from stage I to IV, 12 from stage II to IV, and 12 from stage III to IV. 
When molecular results were added, two additional cases were upstaged 
from stage I, 2 from stage II and 4 from stage III.  
 
Two new revised IPI (rIPI) models were computed for all cases. The first 
(rIPI1) was based on immunophenotyping results alone i.e. flow cytometry 
and immunohistochemistry and the second (rIPI2) on immunophenotyping 
and molecular results. Changes to the IPI essentially occurred when stage of 
disease was upgraded from I or II to stage IV diseases. Of 148 cases where 
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IPI and rIPI were assessable, three cases were upgraded from IPI 0 to a rIPI1 
of 1, 4 cases of IPI 1 changed to a rIPI of 2, 5 cases of IPI 2 were upgraded 
and 6 cases of IPI 3. No changes were noted in IPI 4-5 group. Overall, 18 
patients had a change in their IPI. Of these, three changed their IPI from 0 to 
1, which was not apparent when only four prognostic categories were 
considered. Incorporating molecular results, rIPI2 was found to be upgraded 
in 6, 7 and 6 cases of IPI 0-1, 2 and 3 respectively.  
 
Survival: 
Kaplan Meier curves were created to assess the impact of baseline IPI and 
the two new revised IPI models rIPI1 and rIPI2 on overall survival. Figure 1 
shows the cumulative survival of the four IPI categories using a baseline IPI 
model, a revised model using immunophenotyping (rIPI1) and a revised 
model incorporating molecular studies and immunophenotyping (rIPI2) 
respectively.   All three models were statistically significant with p values of 
<0.0001. 
 
Multivariate analysis: 
Using a multivariate forward stepwise (likelihood ratio method) Cox 
regression, the three IPI models were competitively considered for their 
contribution to predicting survival.  The score tests before inclusion into the 
model were: Baseline IPI: 28.5 (df=3, P<0.001), rIPI1: 31.2 (df=3, p<0.001) 
and rIPI2: 27.9 (df=3, p<0.001). The revised rIPI1 model was then entered 
into the regression model. The hazard ratios of dying relative to the 0/1 IPI 
prognostic categories were:  rIPI1 category 2 = 2.0 [95% CI, 0.61, 6.76, 
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p=0.248], rIPI1 category 3 = 7.6 [95% CI, 2.61, 22.36, p<0.0001], rIPI1 
category 4/5 = 8.9 [95% CI, 2.94, 27.17, p<0.0001]. The baseline IPI model 
and rIPI2 models were excluded from the regression model because they did 
not further contribute to explaining survival [p=0.5, p=0.6 respectively].  
 
Table 2 provides a summary of the relative performances of the three IPI 
models in predicting survival. It can be seen that rIPI1 provides the best 
differentiation between the IPI categories and the largest point estimate 
hazard ratios.  
 
To study the effect of treatment with Rituximab on survival, this too was 
considered, but not found to contribute significantly to the Cox regression 
model (p:0.96). 
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Discussion:  
In this study, we have shown a significant improvement in the predictive value 
of the IPI using ancillary staging investigations, particularly 
immunophenotyping, on the BM. By upstaging a proportion of cases, routine 
use of immunophenotyping provides better differentiation across the IPI 
prognostic categories. This has been confirmed using clinical outcomes in this 
study. These results validate the current guidelines that recommend 
incorporating immunophenotyping in routine staging and suggest the use of a 
new and more inclusive definition of BM involvement within the IPI.  
 
There have been several previous studies on the clinical role of ancillary 
investigations such as flow cytometry (17, 21-25), and IHC (17, 26, 27) in 
NHL, although variable results are noted depending on the histological 
subtypes of NHL.  
 
Overall, multiparametric flow cytometry has been reported to be more 
sensitive than histology alone, and detection of flow cytometry positive cases 
have been reported in 3-11% of histologically negative cases, with rates in 
DLBCL varying from negligible to ~15% (17, 21-23, 25). The converse is also 
true and 5-20% histologically positive DLBCL cases have been reported to be 
negative on flow cytometry (17, 21, 22, 25). This may relate to a number of 
factors such as sampling and adequacy of histological diagnosis. Further 
development of multicolour flow cytometry (6, 8 or 10 colour flow cytometry) 
and its introduction into the clinical laboratory is likely to further improve the 
sensitivity of this technique. 
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Similarly, IHC is reported to detect marrow involvement in histologically 
negative cases in ~10-23% of cases depending on the histological diagnosis 
and the antibodies used (26, 27). This is considered to be due to examination 
of a greater number of levels and also to easier detection of scattered 
malignant cells within normal haemopoietic tissue.  
 
Overall, we found that use of immunophenotyping i.e. flow cytometry and 
immunohistochemistry in staging bone marrow biopsies upstages ~20-22% of 
patients with DLBCL.  The two investigations complement each other. Flow 
cytometry is generally performed on aspirate samples and can be expected to 
add independent prognostic value. Immunohistochemistry, on the other hand, 
is performed on the trephine. Although it does not add independent prognostic 
value, it is a more sensitive technique than histology alone. This study shows 
the value of incorporating these tests as a routine rather than using them in 
histologically ambiguous cases only. Better differentiation into low-risk, low-
intermediate, high-intermediate and high-risk IPI categories is obtained by 
using these tests on all staging bone marrows.  
 
There are several previous studies addressing the role of gene rearrangement 
(IgH/ IgL) studies (28-31) in NHL. Of particular interest is the study by 
Mitterbauer-Hollander et al which showed 16% of histologically negative 
cases had clonal IgH and/ or IgL genes within the bone marrow (31). The 
authors demonstrated a significant difference in overall survival at 5 years 
amongst patients with positive histology and molecular studies, negative 
histology but positive molecular studies, and negative histology and molecular 
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studies. In our study, only ~5% of histologically negative cases were found to 
have rearranged immunoglobulin genes. We were unable to demonstrate a 
difference in overall survival or a change in the predictive value of the IPI by 
inclusion of molecular staging. This is likely to be related to the unavailability 
of archived fresh frozen trephine tissue or DNA for our study resulting in all 
molecular analyses being performed on FFDPE trephine tissue. This is in 
contrast to the previous study, in which all molecular analyses were 
performed on fresh bone marrow aspirates (31). It is well known that fresh 
tissue yields better quality DNA compared to FFDPE tissue (32).  It should 
also be noted that the BIOMED2 based protocols are not as well established 
on FFDPE tissue (19), although occasional groups have modified the 
protocols with improved results (33). It may be of interest to determine if the 
use of such modified protocols would improve the prognostic significance of 
molecular staging on FFDPE tissue. Other alternatives to PCR staging may 
be staging using Fluorescent in-situ hybridisation (FISH) probes with some 
recent literature demonstrating that FISH using IgH/ BCL2 may give improved 
results as compared to PCR on paraffin-embedded sections (34).  
 
Besides the obvious advantage of availability of archived trephine biopsy 
tissue, the other reason for choosing to perform molecular staging on trephine 
biopsy rather than aspirate is that histological bone marrow involvement is 
noted more commonly on trephine biopsies. This has been demonstrated in 
previous studies (35) and largely attributed to sampling and the tendency of 
lymphoma cells to adhere to bony trabeculae (36). As such, there would be 
greater likelihood of detecting clonal gene rearrangements on trephine biopsy 
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rather than aspirate samples. Collecting additional trephine biopsy samples 
for such testing may be logistically difficult.  Improved DNA extraction 
methods and optimal modification of the BIOMED2 protocols for FFDPE 
trephine tissue may be the best realistic option.  
 
There are several limitations of our study. This is a small retrospective study 
in DLBCL cases at initial diagnosis. As only a proportion of cases were 
treated with Rituximab in this study, we used multivariate analysis to 
demonstrate that it was not a significant confounding factor in our analysis. 
However, we acknowledge a prospective study may be required to confirm 
that the results are valid in Rituximab treated patients. The other major 
limitation is the use of archived rather than fresh trephine tissue for molecular 
staging due to the logistics of obtaining fresh trephine tissue in our centre. We 
acknowledge that we may have been able to demonstrate improvement in the 
prognostic significance of the IPI using gene rearrangement studies if fresh 
tissue had been analysed.  
 
Despite the limitations of our study, we were able to demonstrate an 
improvement in the prognostic significance of the IPI by use of simple, 
relatively inexpensive and readily available staging investigations such as flow 
cytometry and IHC. Our results suggest that a large prospective study is 
warranted to assess the impact of staging investigations on the IPI in a more 
homogenously treated DLBCL population.  
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Conclusions: 
• The predictive value of the IPI can be improved significantly by the routine 
use of immunophenotyping on staging bone marrow biopsy.  
• Immunophenotyping i.e. flow cytometry and immunohistochemistry should 
be recommended as routine investigations on all bone marrows at initial 
diagnosis, as the detection of occult disease in morphologically normal 
marrow affects clinical outcome in DLBCL.  
• In this study, molecular analysis did not further contribute in improving the 
prognostic significance of the IPI. This is likely to have been due to technical 
limitations. 
• Larger prospective studies are warranted to assess the impact of staging 
investigations including gene rearrangement studies on the IPI in a more 
homogenously treated DLBCL population.  
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Figure legends: 
 
Figure 1: The three Kaplan Meier curves show differences in cumulative 
survival between with low-risk, low-intermediate, high-intermediate and 
high-risk categories using a baseline IPI model (A) and two revised IPI 
models. The first (rIPI1) incorporates flow cytometry and 
immunohistochemistry as routine staging (B) and the second IPI model 
(rIPI2) additionally incorporates molecular testing using IgH/ IgL 
analysis (C).   
 
 
 33
Table 1: Results on immunoglobulin heavy chain (IgH) and light chain 
(IgL) gene rearrangement studies  
 
 #IGK +ve IgK –ve Total 
*FR3 +ve 13 5 18 
**FR3 –ve 21 116 137 
Total 34 121 155 
FR1 +ve 2 2 4 
FR1 –ve 32 119 151 
Total 34 121 155 
* FR1: framework I 
** FR3: framework III 
# IGK: immunoglobulin kappa 
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Table 2: Summary table showing the hazard ratios from Cox regression 
analyses for the three IPI models, baseline IPI, rIPI1 and rIPI2  
 
 rIPI1# 
Hazard ratios  
(95% CI) 
 
Baseline IPI† 
Hazard ratios  
(95% CI) 
 
rIPI2‡ 
Hazard ratios 
(95% CI) 
 
Low-risk IPI  
(score 0/1) 
Reference Reference Reference 
Low-intermediate 
IPI 
(score 2) 
2.0 (0.61, 6.76) 
p=0.248 
 
1.56 (0.54, 4.51) 
P=0.4 
1.8 (0.5, 6.0) 
P=0.3 
High-intermediate 
IPI 
(score 3) 
7.6 (2.61, 22.36) 
p<0.0001 
 
5.32 (2.14, 13.22) 
P<0.0001 
6.4 (2.2, 18.6) 
P=0.001 
High-risk IPI (score 
4/5) 
8.9 (2.94, 27.17) 
p<0.0001 
 
6.9 (2.61, 18.32) 
P<0.0001 
8.1 (2.7, 24.6) 
P<0.001 
#Cox regression using forward likelihood ratio method (Χ2: 31.5, df=3, p<0.0001) 
†Cox regression entering baseline IPI into the model first (Χ2: 27.4, df=3, p<0.0001) 
‡Cox regression entering rIPI2 in to the model first (Χ2: 28.2, df=3, p<0.0001) 
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